title: Effect of bismuth salts on systemic and mucosal immune responses to orally administered cholera toxin.
abstract: While the antimicrobial and antisecretory effects of bismuth salts are well documented, little is known regarding their effects on immune responses to enterotoxins such as that of V. cholerae or to orally administered vaccine antigens. To evaluate the effects of Pepto Bismol (PB) on the induction of systemic and mucosal immune responses to cholera toxin (CT), C57BL/6 mice were orally administered 10 micrograms CT and PB, or mice were pretreated with PB 30 min prior to CT administration. When co-administered with CT, PB attenuated serum IgG1, IgG2a, IgG2b and IgG3 anti-CT responses in a dose-dependent manner and also reduced levels of circulating anti-CT IgA and total serum IgE. Similarly, anti-CT intestinal IgA responses were also decreased. However, when administered 30 min prior to CT, PB had little to no effect on serum or intestinal anti-CT immunoglobulin responses. Administration of bismuth subsalicylate (BSS), the active component of PB, or sodium salicylate did not reduce immune responses to CT, suggesting that the combination of BSS plus other constituents contained within PB contributed to the decreased immune response to CT. Moreover, bismuth subgallate alone inhibited antibody responses to CT. Our data are consistent with the hypothesis that, when administered orally with CT, PB and bismuth subgallate create a physical barrier to antigen uptake.
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: N S
authors.initials: NS
authors.lastname: Horowitz
authors.forename: H F
authors.initials: HF
authors.lastname: Staats
authors.forename: T J
authors.initials: TJ
authors.lastname: Palker
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000992:Antitoxins / Q000032:analysis / Q000276:immunology*; D001729:Bismuth / Q000494:pharmacology*; D002772:Cholera Toxin / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005243:Feces; D005260:Female; D018928:Immunity, Mucosal; D007114:Immunization; D007070:Immunoglobulin A / Q000096:biosynthesis / Q000097:blood; D007073:Immunoglobulin E / Q000096:biosynthesis / Q000097:blood; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D051379:Mice; D008810:Mice, Inbred C57BL; D009942:Organometallic Compounds / Q000494:pharmacology; D012459:Salicylates / Q000494:pharmacology; D012980:Sodium Salicylate / Q000494:pharmacology; D013997:Time Factors
chemical_list: D000992:Antitoxins; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009942:Organometallic Compounds; D012459:Salicylates; D007073:Immunoglobulin E; C015715:bismuth subsalicylate; D002772:Cholera Toxin; D001729:Bismuth; D012980:Sodium Salicylate